Efficacy of Herbal Interventions in Oral Lichen Planus: A Systematic Review

Abstract

Introduction: Oral lichen planus (OLP) is a chronic autoimmune condition requiring prompt treatment to alleviate the signs and symptoms. There is weak evidence emphasizing the efficacy of any one therapy. Steroids, of all the therapies, have proved to be effective and hence considered as the standard care for OLP. However, the complications associated with it further worsen the patient’s condition. Alternative safe approaches such as herbal interventions (HIs) have been tried in OLP. Their efficacies could only be evaluated from properly designed research protocols such as randomized controlled trials (RCTs). The present systematic review aims to assess the efficacy of HIs compared to steroids in RCTs involving OLP. Materials and Methods: An extensive search for HIs in OLP was conducted in PubMed, MEDLINE, Cochrane Central Register of Controlled Trials, Scopus, and gray literature. Eight studies fulfilled the eligibility criteria. Results: In all the studies, clinical severity was significantly reduced in within-group comparisons, whereas between-group comparisons showed nonsignificant results, except for total glucosides of paeony capsules. Conclusion: Efficacy of herbal therapy in OLP should be weighed against the high bias in the studies.

Keywords: Herbal, intervention, oral lichen planus, randomized controlled trial, steroid.

Introduction

Oral lichen planus (OLP) is a chronic, T cell-mediated autoimmune disease characterized by periods of exacerbations and remissions.[1‑5] A female predominated condition, OLP could also be associated with systemic conditions such as diabetes mellitus and hypertension.[5‑7] It manifests in various forms such as plaque, reticular, papular, atrophic, erosive, and bullous.[9] Periods of exacerbations are usually associated with atrophic or erosive forms which lead to severe pain or burning sensation. Various treatment strategies have been tried, with variable results.[9,10] Corticosteroids have been the main drug of choice in these patients.[11] However, considering the chronic nature of the condition, associated systematic diseases, and frequent use of steroids, the number of patients affected by the complications is uncountable. In addition to the systemic complications, long-term topical corticosteroids can lead to secondary candidiasis, taste alterations, mucosal atrophy, and burning sensation, further worsening the condition.[12‑14] Therefore, an alternative and safe therapy which could be equally effective or superior to steroids should be explored.

One such therapy is the herbal medicines which have been tried for many chronic conditions including OLP.[15,16] Randomized controlled trials (RCTs) of herbal interventions (HIs) with steroids as standard control will give an unbiased insight to the current scenario of range of herbal therapies which could be alternatively given in OLP patients. Thus, the present systematic review was planned with the basic research question: “How efficacious are the herbal medicines as compared to corticosteroids in RCTs on symptomatic OLP patients?”

Materials and Methods

Eligibility criteria

1. Types of studies: The studies included were RCTs comparing herbal medicine with corticosteroid, with or without blinding of the participants and the outcome assessors. Quasi randomized trials, nonrandomized trials, crossover studies, case reports, and split-mouth studies were excluded

2. Intervention types: Studies with herbal and corticosteroid interventions in any
form, either topical or systemic or intraleisional and in varying doses, were included. In addition, studies comparing different HI or trials with placebo as one of the groups along with steroid intervention were also included. Studies not involving corticosteroids were excluded.

3. Participants: Studies involving histopathologically confirmed and symptomatic cases of OLP of any age, gender, or race were included. Whereas, participants with idiopathic, plaque type, nonsymptomatic OLP, or individuals with lichenoid drug reaction or showing evidence of dysplasia and those who have missed the follow-up or recall visits were also excluded.

4. Primary outcome: Studies assessing relief in symptoms such as pain, burning, or discomfort as stated by the participants measured by visual analog scale (VAS) or numeric rating scale (NRS) or any other related scale were included.

5. Secondary outcome: Studies involving following secondary outcome measuring parameters were included:
   a. Reduction in clinical signs that is the size and severity of the lesions measured by appropriate clinical scoring system.
   b. Improvement in clinical response or restoration of normal function judged by the improvement index.
   c. Reduction in the interference with daily activities or improvement in quality of life judged by quality of life index/questionnaire.
   d. Reduction in the severity and flare.
   e. Relapse after discontinuation of medicine.
   f. Adverse effects if any reported.

The outcomes should have been assessed periodically either in days, weeks, or months.

The protocol of the study was registered in PROSPERO with the registration no: CRD42018114116.

Searching sources and strategy

The sources for search of relevant RCTs were from electronic databases of PubMed, MEDLINE, Cochrane Central Register of Controlled Trials, and Scopus from January 2000 to October 2018 with no restrictions for any language. In addition, National Institute of Health Trials, knowledge Hub e-library, Clinical Trials Registry of India, Google Scholar, and EBSCOHost along with manual searching from citations, bibliographies, review articles, and major journals related to the topics were also searched. The search strategy is shown in Table 1. The keywords were validated by the MeSH (Medical Subject Headings) dictionary, and the Boolean operator AND was used to relate them.

Screening and selection

The studies in the form of titles and/or abstracts obtained after using search strategy (including all sources) were screened independently by two review authors (A and C). The duplicate studies were removed, and the full texts of those studies which fulfilled the eligibility criteria mentioned above were retrieved and independently assessed for eligibility. Any disagreements between the reviewers were resolved by discussion with the third reviewer (B) [Table 1].

Data extraction and quality assessment

The data were extracted from the selected articles independently by two reviewers (D and E) in a standardized pre-piloted form [Table 2], and discrepancy if identified was resolved by discussion with the third reviewer (B). Contacts were established with the authors of articles having missing data and were requested to provide the same. Quality assessments of RCTs were done by Cochrane risk-of-bias tool for RCTs.[17]

Results

Search and selection results

After an extensive search of database and other sources as mentioned previously, the data were gathered. Details of data collection, screening, and selection procedure are summarized in flowchart shown in Figure 1. After removal of the duplicate articles and retrieval of full-text articles (14) for screening for the eligibility criteria, six articles were excluded and finally the remaining eight articles were considered for systematic review.

| Table 1: Search strategy keywords |
|-----------------------------------|
| Concepts                          | Search strategy                          |
| Lichen planus OR lichen planus, oral | Herbal therapy OR herb therapy OR phytotherapy |
| Herbal therapy                    | OR plant extracts OR plants, medicinal OR herbalism OR curcumin OR aloe vera OR anthocyanins OR quercetin OR lycopene OR propolis OR honey OR Chinese herbs |
| Steroids                          | Steroids OR Corticosteroids OR triamcinolone acetonide OR clobetasole propionate OR dexamethasone OR prednisolone OR betamethazone |

| Table 2: Points included in data extraction form |
|-------------------------------------------------|
| Study setting                                   |
| Study population                                |
| Participant demographics and baseline characteristics |
| Details of herbal intervention and steroid intervention |
| Study methodology                                |
| Recruitments and study completion rates          |
| Scales used to measure the outcomes             |
| Outcomes and times of measurement               |
| Indicators of acceptability by user and adverse effects |
| Risk of bias assessment                         |
Characteristics of eight studies included for the systematic review [Table 3]

All the included studies were prospective RCTs carried out in secondary care centers. Studies included clinically and histopathologically were proven cases of OLP. A total of 354 (males = 117 and females = 237) symptomatic OLP participants participated in the trials with a mean of 44 per study, female predominance, and an age range of 18–75 years. The commonly involved oral mucosal areas were buccal mucosa followed by tongue and gingiva. Types of lesions commonly observed in the participants were mixed, erosive, atrophic, and reticular types in descending order. The trials included steroids in topical form in all studies except one.[18‑25] In this last study, two types of steroids, dexamethazone (0.1% gel) and prednisolone (capsule 15mg), were given topically and orally, respectively, in two different arms.[25] The topical steroids included triamcinolone acetate 0.01% in gel and paste forms and dexamethazone acetate 0.1% in gel and mouthwash (0.5mg) forms.[18‑25] Two studies had an additional placebo group.[20,23] HIs included curcuminoids in three studies and aloes vera, cedar honey, quercetin, glucosides of paony, and lycopene in the remaining five studies each.[18‑25] The modes of administration of HI were as follows: curcuminoids were administered systemically in the form of tablets,[23] and topically in the form of paste and gel, and total glucosides of paony and lycopene were administered systemically in the form of capsules and pills, respectively, and aloes vera mouthwash in the form of topical therapy had to be expectorated whereas cedar honey liquid had to be swished and swallowed.[18,19,21‑25] One study included the same intervention in different arms with different dosing patterns (curcuma longa extract 10 mg in gel form thrice for 3 months in one arm and six times for 3 months in another arm).[24] Antimycotic drugs, fluconazole capsules 100 mg and nystatin suspension 10,000 U, were administered in two studies, whereas 1% sodium bicarbonate rinse was administered in another study.[19,20,22,23]

Outcomes

Assessment criteria for outcome were found to vary across the studies. For the evaluation of burning sensation and pain, out of the eight included studies, four studies used only VAS, two studies used NRS, and two studies used VAS and pain index.[18‑25] Clinical response of decrease in size and severity of lesion was measured in all trials but by different grading methods. Thongprasom clinical grading criteria were used by five studies and modified oral mucositis index (MOMI) in one study.[18,21‑25] Two studies evaluated clinical response by severity index and severity improvement.[19,20] Size measurements were done with sterile caulis, periodontal probe, and grids, whereas few studies did not specify their methods of measurements of lesion size.[18‑25]

Times of follow-up measurement

Six studies had a total follow-up time of 4 weeks, one had a follow-up time of 3 months, whereas another study had 6 months of follow-up time.[18‑25]

Effects of herbal intervention versus steroids

Statistically nonsignificant difference was noted between the HIs and the steroid interventions in terms of relief
| Studies               | Number of groups (G) with number of participants in each and type of intervention received | Herbal intervention type with dose and duration | Steroid intervention type with dose and duration | Adverse effects                                                                 | Outcome evaluations                                                                 |
|----------------------|--------------------------------------------------------------------------------------------|-----------------------------------------------|-----------------------------------------------|--------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| Mansourian et al., 2011[18] | G1=23 Intervention: Herbal G2=23 Intervention: Steroid | Aloe Vera mouthwash 2 tablespoons for 2 min, QID for 1 month | Triamcinolone acetonide 0.1%, thin layer application, QID for 1 month | - | Evaluated by VAS: Statistically nonsignificant difference between the two groups |
| Sanatkhan et al., 2014[19] | G1=15 Intervention: herbal + steroid G2=15 Intervention: steroid | Cedar honey, 20 ml TDS via the swish and swallow technique for 4 weeks | Dexamethasone mouthwash, 0.5 mg QID and fluconazole capsule 100 mg OD for 4 weeks | Mild burning sensation in G 1 cases | Evaluated by VAS and pain index: Statistically nonsignificant difference between the two groups |
| Amirchaghmaghi et al., 2015[20] | G1=15 Intervention: herbal + steroid G2=15 Intervention: steroid + Placebo capsules | Quercetin hydrate Capsule 250mg, two capsules BD for 4/8 weeks | Dexamethasone mouthwash 0.5 mg, QID along with nystatin suspension 10,0000 U | Well tolerated | Evaluated by VAS and pain index: Statistically nonsignificant difference between the two groups |
| Kia et al., 2015[21] | G1=25 Intervention: herbal G2=25 Intervention: steroid | Curcuminoid 5% paste, TDS for 4 weeks | Triamcinolone acetonide 0.1% paste TDS for 4 weeks | G 1=Burning sensation, itching, mild swelling, xerostomia and yellowish discoloration of gingiva G 2=Burning sensation, mucosal desquamation | Evaluated by VAS : Statistically nonsignificant difference between the two groups |

Contd...
| Studies                          | Number of groups (G) with number of participants in each and type of intervention received | Herbal intervention type with dose and duration | Steroid intervention type with dose and duration | Adverse effects | Outcome evaluations | Other |
|---------------------------------|-------------------------------------------------------------------------------------------|------------------------------------------------|------------------------------------------------|-----------------|--------------------|-------|
| Zhou et al., 2016<sup>22</sup>  | G1 ROLP<sup>ab</sup>  
A: n=17  
Intervention: topical steroid  
B: n=22  
Intervention: herbal + topical steroid  
G2 EOLP  
C: n=17  
Intervention: systemic steroid  
D: n=17  
Intervention: herbal + systemic steroid | Total glucosides of paony capsule 200 mg capsules, 400 mg TDS, once a month for 6 months | Topical: Dexamethasone acetate 0.1%, BD until symptom resolution  
1% sodium bicarbonate rinses  
Systemic: prednisolone 15 mg daily for 1 month until symptom resolution followed by tapering | Diarrhea | Evaluated by VAS: Statistically significant difference between ROLP A and ROLP B (<0.05)  
and EOLP C and EOLP D (<0.01), at 4th and 6th months | - |
| Amirchaghma-ghi et al., 2016<sup>23</sup> | G1=12  
Intervention: herbal + steroid  
G2=8  
Intervention: steroid + Placebo capsules | Curcuminoid tablets 500 mg, four tablets BD for 4 weeks | Dexamethasone mouthwash 0.5 mg, QID alongwith nystatin suspension 10,000 U | Well tolerated | Evaluated by VAS: Statistically nonsignificant difference between the two groups | - |
| Thomas et al., 2017<sup>24</sup>  | G1=25  
Intervention: steroid  
G2=25  
Intervention: herbal (a)  
G3=25  
Intervention: herbal (b) | Curcuma longa extracts 10 mg gel thrice for 3 months  
Curcuma longa extracts 10 mg gel six times for 3 months | Triamcinolone acetonide 0.1% oral paste thrice with tapering | Well tolerated | Evaluated by numeric rating scale: Statistically nonsignificant difference between the three groups | - |
| Arbabi-Kalati and Farahmand 2017<sup>25</sup>  | G1=15  
Intervention: herbal + steroid  
G2=15  
Intervention: herbal | Lycopene pill of 15 mg OD for 1 month | Triamcinolone acetonide 0.1% oral paste QID for a month | - | Evaluated by numeric rating scale: Statistically nonsignificant difference between the two groups | - |

QID: Four times daily, VAS: Visual analog scale; TDS=Thrice daily, OD: Once daily, BD: Twice daily, ROLP: Reticular oral lichen planus, EOLP: Erosive oral lichen planus, MOMI: Modified oral mucositis index
in burning sensation and decrease in size and severity of lesions in all the RCTs, except one in which statistically significant difference was noted.\textsuperscript{[18‑22,23‑25]} In this last study, the HI groups received total glucosides of paeony capsules (TGPC) along with topical dexamethasone 0.1% in one group and TGPC along with prednisolone 15 mg in another group, which were compared with only steroid intervention groups receiving dexamethasone 0.1% and prednisolone 15 mg, respectively.\textsuperscript{[22]} The effect measures at different follow-up periods also showed higher improvement rates in HI groups along with steroid groups as compared to steroid intervention group alone. Improvement index done by three studies showed statistically nonsignificant difference.\textsuperscript{[19‑21]}

**Adverse effects** [Table 3]

Quercetin and curcuminoids in gel and tablet forms were well tolerated, but participants receiving curcuminoids in paste form reported of burning, itching, desquamation, and discoloration of gingiva and xerostomia.\textsuperscript{[20,21,23‑24]} Mild burning and diarrhea have been reported by cedar honey and TGPC.\textsuperscript{[19‑22]} Adverse effects related to the use of aloe vera and lycopene were not reported. Adverse effects to steroids were reported as burning sensation and mucosal desquamation.\textsuperscript{[18,21‑25]}

Only two studies followed up the participants after discontinuation of the intervention for 1 month and no recurrences were reported by any of the studies.\textsuperscript{[18,20]}

**Risk of bias assessment** [Table 4]

The included RCTs (n = 8) were assessed for risk of bias by the Cochrane risk-of-bias tool for RCTs [Appendix D].\textsuperscript{[17]} The studies were individually assessed under the following five domains: selection, performance, attrition, reporting, and other bias. The judgment of risk of bias was given as low, unclear, or high for each of the five domains and accordingly the quality was graded as having low risk, moderate risk, or high risk of bias. Table 2 summarizes the risk of bias assessment of the eight studies included in the present review.

**Selection bias**

Random allocation of the participants to the study arms ensures minimization of selection bias. Out of the 8 shortlisted studies, few used an electronic random number generator to create a list of random number, whereas others used random numbering table and simple randomization method.\textsuperscript{[18‑20,22‑25]} Block randomization was used by two studies with block size of six in one study and quota sampling method in another.\textsuperscript{[21‑24]}

**Allocation concealment**

Pharmacy controlled randomization was advocated in four studies, whereas others did not specify their method of allocation concealment.\textsuperscript{[18‑25]}

**Selective reporting**

All the studies reported their prespecified outcomes, except one. This study did not specify the outcomes during the follow-up visits.\textsuperscript{[25]}

**Other bias**

All the eight studies appeared free of other sources of bias.

**Blinding**

In four studies, both participants and outcome assessors were blinded.\textsuperscript{[18‑20,21‑23]} In two studies, only outcome assessors were blinded, whereas in two studies, nothing has been addressed about blinding.\textsuperscript{[19‑22,24‑25]}

**Incomplete outcome data**

Primary and secondary outcomes were adequately reported by all the studies. Four studies reported the number of attrition or exclusions along with the reasons, whereas two studies did not address anything on this matter as all the enrolled participants completed the study.\textsuperscript{[18,19,21‑25]} Less than 10% dropout rate was observed in three studies, whereas dropout rate between 10% and 20% was observed in one study.\textsuperscript{[18,21‑22,24]}

Meta-analysis of the pooled data could not be performed due to marked heterogeneity among the included studies. The main reasons were as follows: variations in the HIs and the steroid interventions along with variations in the modes of drug delivery and dosing patterns, variations in the assessment criteria of outcome variables, and variations also in their reporting.

**Discussion**

Efficacy of a new therapy could be judged only when it is compared with the standard or active intervention under standard conditions. Corticosteroids for OLP could be considered as standard intervention as its efficacy has already been proven earlier, but its use could be limited due to the complications associated with it.\textsuperscript{[26,27]} Currently, natural therapies have gained lots of momentum. Being natural, they are abundant, safe, and cost-effective which could have let to their trials in various health-related problems. OLP is one such condition, in which herbal therapies have also been tried. Being a chronic autoimmune condition, OLP is associated with interference in daily life activities which could adversely affect the psychological well-being of the patient. Till date, complete cure of OLP has not been evidenced. Most of the patients experience recurrence of lesions with symptoms and this could lead to a poor quality of life. Evidence from the clinical trials could help researchers and clinicians to provide a safe and effective therapy for long term. Furthermore, the various constituents in a single herb accommodate a host of responses which could be beneficial from complete health point of view. Considering this perspective, a systematic
Table 4: Risk of bias assessment of the eight included randomized control trials

| Studies                          | Random sequence generation                                      | Allocation concealment                        | Selective reporting | Other bias                        | Blinding of participants | Blinding of outcome assessment | Incomplete outcome data | Quality assessment          |
|----------------------------------|-----------------------------------------------------------------|-----------------------------------------------|---------------------|----------------------------------|--------------------------|-------------------------------|---------------------------|--------------------------|
| Mansourian et al., 2011[18]      | Low (random number generated through software)                  | Low (identical sealed packet of medication to be picked up from the pharmacist) | Low (all outcomes reported) | Low (no other bias detected)     | Low (subjects were blinded)  | Low (outcome assessors blinded) | Low (outcome data was complete) | Low risk of bias            |
| Sanatkhani et al., 2014[19]      | Low (electronic random number generator was used)              | Unclear (not described in sufficient detail) | Low (all outcomes reported) | Low (no other bias detected)     | High (subjects not blinded)  | Low (outcome assessors blinded) | Low (outcome data was complete) | High risk of bias           |
| Amirchaghmaghi et al., 2015[20]  | Low (Random number generated through software)                 | Low (identical capsules of interventions provided by the pharmacist) | Low (all outcomes reported) | Low (no other bias detected)     | Low (subjects were blinded)  | Low (outcome assessors blinded) | Low (outcome data was complete) | Low risk of bias            |
| Kia et al., 2015[21]             | Low (Blocked randomization was done)                            | Low (similar oral pastes provided)           | Low (all outcomes reported) | Low (no other bias detected)     | Low (subjects were blinded)  | Low (outcome assessors blinded) | Low (outcome data was complete) | Low risk of bias            |
| Zhou et al., 2016[22]            | Low (Random numbering table was used)                           | Unclear (not described in sufficient detail) | Low (all outcomes reported) | Low (no other bias detected)     | High (subjects not blinded)  | Low (outcome assessors blinded) | Low (outcome data was complete) | High risk of bias           |
| Amirchaghma-ghi et al., 2016[23]| Low (Computer-generated random number table was used)          | Low (identical tablets in identical containers were provided) | Low (all outcomes reported) | Low (no other bias detected)     | Low (subjects were blinded)  | Low (outcome assessors blinded) | Low (outcome data was complete) | Low risk of bias            |
| Thomas et al., 2017[24]          | Low (simple randomization was done)                             | Unclear (not described in sufficient detail) | Low (all outcomes reported) | Low (no other bias detected)     | Unclear (not described in sufficient detail) | Unclear (not described in sufficient detail) | Low (outcome data was complete) | High risk of bias           |
| Arbabi-Kalati and Farahmand 2017[25] | Low (blocked randomization was done)                           | Unclear (not described in sufficient detail) | Unclear (insufficient information regarding outcomes during the follow-up visits) | Low (no other bias detected) | Unclear (not described in sufficient detail) | Unclear (not described in sufficient detail) | Low (outcome data was complete) | High risk of bias           |
review to evaluate the efficacy of HI as compared to standard intervention by corticosteroids was planned.

Adjuvant therapy is given with the motive of providing synergistic action and enhancing faster relief. In the present review, seven RCTs showed nonsignificant differences between the HI and SI.\(^{[18-21,23-25]}\) Out of these, in four RCTs, the participants received HI as an adjuvant to corticosteroids.\(^{[19,20,23,25]}\) In these studies, it is difficult to comment on the role of herbal medicines, as in all these four studies, the result is statistically nonsignificant. If the results would have been statistically significant, it would have been easy to comment on the synergistic action of HI with that of steroid in enhancing faster relief. On the contrary to this, in one study, TGPC was given as an adjuvant to steroid and had shown significant result, but the contrary to this, in one study, TGPC was given as an adjuvant to steroid and had shown significant result, but the study was at a very high risk of bias.\(^{[22]}\) In the remaining three RCTs, the participants received only HI compared to only steroid intervention. The results were nonsignificant, indicating that HI was equally effective to that of SI in resolving the signs and symptoms of OLP.\(^{[18,21,24]}\) The HI included in these studies were aloe vera mouthwash, curcuminoide paste, and curcuma longa extract gel.\(^{[18,21,24]}\) Thus, aloe vera mouthwash and curcuminoid paste could be considered equally effective to that of steroid as the risk of bias in these studies was also low.\(^{[18,21]}\) Alternatively, aloe vera mouthwash and curcuminoid paste could be considered as a substitute therapy in place of steroids in OLP patients. However, it would be difficult to comment on the efficacy of curcuma longa extract gel, as the study has a higher risk of bias.\(^{[24]}\)

Curcumin has shown to exhibit antioxidant, anti-inflammatory, antimicrobial, and anticarcinogenic activities.\(^{[25]}\) It is safe even at high doses, albeit with occasional side effects such as diarrhea.\(^{[25,29]}\) Aloe vera also exhibits anti-inflammatory action by virtue of its cyclooxygenase inhibition action and decrease in the leukocyte adhesion molecules and tumor necrosis factor alpha levels.\(^{[30]}\) In addition, it also has antioxidant properties.\(^{[31]}\)

Herbal therapy has the advantage of providing multiple pharmacological effects mainly due to the combination of various phytoconstituents available in a single herb. This could be the reason for its utilization in various health-related problems. The herbal medicines tried in OLP mainly curcumin, aloe vera, honey, propolis, quercetin, lycopene, and glucosides of paenony, all have proved to have anti-inflammatory, antioxidant, and immunomodulatory properties. However, their mostly nonsignificant results in the trials could be due to the insufficient doses or the forms, in which they might have been tried. Thus, more stringent protocols of RCTs with varying doses and forms of intervention should be carried out to provide evidence for the efficacy of herbal therapies in OLP.

Previous systematic reviews on interventions in treating OLP included RCTs involving all types of interventions (including herbal) compared with placebo or other active treatment. They stated insufficient evidence to comment on the effectiveness or superiority of any specific intervention in reducing signs and symptoms of OLP.\(^{[12,33]}\) In the present systematic review, only those RCTs on OLP patients were included which had HIs compared to standard treatment (corticosteroids). Apart from the two RCTs involving curcumin and aloe vera, in the present review also, the remaining RCTs provided questionable evidence to support herbal therapy effectiveness.

Limitations and recommendations

The relatively less number of RCTs with different HIs, in different forms and doses, varying study designs, different scoring patterns for outcome evaluations, and different follow-up intervals warrant more research in this area, but with uniformity in the abovementioned aspects. Efforts should also be taken to reduce the amount of bias in the RCTs.

This would enable one to draw a meta-analysis to further confirm the efficacy of individual herbal medications over steroids in a larger sample. Furthermore, the RCTs should encourage herbal medications either alone or as an adjuvant therapy to steroids to confirm their respective efficacies. To ensure long-term benefits of medications, longer follow-up periods should also be planned along with assessment of quality of life.

Conclusion

Although two RCTs involving curcumin (Mansourian et al. 2011) and aloe vera (Kia et al. 2015) as the herbal therapy have shown promising results in resolving the signs and symptoms of OLP, the present systematic review suggests insufficient evidence to support most of the other herbal therapies.\(^{[18,21]}\) To confirm their efficacy, more research in standard conditions (RCTs with low risk of bias) is required.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1. Sugerman PB, Savage NW, Walsh LJ, Zhao ZZ, Zhou XJ, Khan A, et al. The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med 2002;13:350-65.
2. Stooppler ET, Sollecito TP, De Rossi SS. Oral lichen planus. Update for the general practitioner. N Y State Dent J 2003;69:26-8.
3. Mollaoglu N. Oral lichen planus: A review. Br J Oral Maxillofac Surg 2000;38:370-7.
4. Eisen D. The clinical manifestations and treatment of oral lichen planus. Dermatol Clin 2003;21:79-89.
5. Edwards PC, Kelsch R. Oral lichen planus: Clinical presentation
and management. J Can Dent Assoc 2002;68:494-9.
6. Scully C, Beyli M, Ferreiro MC, Ficarra G, Gill Y, Griffiths M. Update on oral lichen planus: Etiopathogenesis and management. Crit Rev Oral Biol Med 1998;9:89-122.
7. Roopashree MR, Gondhalekar RV, Shashikanth MC, George J, Thippeswamy SH, Shukla A. Pathogenesis of oral lichen planus—a review. J Oral Pathol Med 2010;39:729-34.
8. Krasteva A, Krasteva A, Kisselova. Topical Corticosteroids in Oral Pathology. Vol. 16. Journal of IMAB-Annual Proceeding in Oral Pathology. Vol. 80-4.
9. Thingprasom K, Dhanuthai K. Steroids in the treatment of lichen planus: A review. J Oral Sci 2011;342:51-47.
10. Dhar S, Seth J, Parikh D. Systemic side-effects of topical corticosteroids. Indian J Dermatol 2014;59:460-4.
11. Singh V, Pal M, Gupta S, Tiwari SK, Malikunje L, Das S. Turmeric a new treatment option for lichen planus: A pilot study Natl J Maxillofac Surg 2013;4:198-201.
12. Karem El-Soudany, Yagi A, Kabbash A. A self-controlled single blinded clinical trial to evaluate oral lichen planus after topical treatment with Aloe vera. J GHR 2013;21:503-7.
13. Gupta S, Jawanda MK. Oral lichen planus: An update on etiology, pathogenesis, clinical presentation, diagnosis and management. Indian J Dermatol 2015;60:222-9.
14. Thingprasom K, Carrozzo M, Furness S, Lodi G. Interventions for treating oral lichen planus. Cochrane Database Syst Rev 2011;7:CD001168.
15. Cheng S, Kirtschig G, Cooper S, Thornhill M, Leonardis-Bee J, Murphy R. Interventions for erosive lichen planus affecting mucosal sites. Cochrane Database Syst Rev 2012;2:CD008092.
16. Thingprasom K, Dhauthai K. Steroids in the treatment of lichen: A review. J Oral Sci 2008;50:377-85.
17. Higgins JPT, Green S. In: Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration. Hoboken, New Jersey: John Wiley and Sons, Ltd; 2011.
18. Mansourian A, Momen-Heravi F, Saheb-Jamee M, Esfahani M, Khalilzadeh O, Momenn-Beitolahi J. Comparison of Aloe vera mouthwash with triamcinolone acetoniode 0.1% on oral lichen planus: A randomized double-blinded clinical trial. Am J Med Sci 2011;342:51-47.
19. Sanatkhani M, Mozafari PM, Amirchaghmaghi M, Fathi MN, Sanatkhani M, Sarjami N, et al. Effect of cedar honey in the treatment of oral lichen planus. Iran J Otitohrinolaryngol 2014;26:151-61.
20. Amirchaghmaghi M, Delavarian Z, Iranshahi M, Shakeri MT, Mozafari PM, Mohammadpour AH, et al. A randomized placebo-controlled double blind clinical trial of quercetin for treatment of oral lichen planus. J Dent Res Dent Clin Dent Prospect 2015;9:23-8.
21. Kia SJ, Shirazian S, Mansourian A, Fard LK, Ashnagar S. Comparative efficacy of topical curcumin and triamcinolone for oral lichen planus: A Randomized, controlled clinical trial. J Dent Tehran Univ Med Sci 2015;12:789-96.
22. Zhou L, CaoT, WangY, Yao H, Du G, Tian Z, et al. Clinical observation on the treatment of oral lichen planus with total glucosides of paeony capsule combined with corticosteroids. Int Immunopharmacol 2016;36:106-10.
23. Amirchaghmaghi M, Pakfetray A, Delavarian Z, Ghalavani H, Ghazi A. Evaluation of the Efficacy of curcumin in the treatment of oral lichen planus: A randomized controlled trial. J Clin Diagn Res 2016;10:134-7.
24. Thomas EA, Varma B, Kurup S, Jose R, Chandy ML, Kumar SP, et al. Evaluation of efficacy of 1% curcuminoids as local application in management of oral lichen planus intervention study. J Clin Diagn Res 2017;11:89-93.
25. Arzabi-Kalati F, Farahmand MM. Evaluation of the efficacy of lycopena in the management of oral lichen planus: A pilot randomized clinical trial. Tehran Univ Med J 2017;75:658-62.
26. Lopez-Jornet P, Camacho-Alonso F, Salazar-Sanchez N. Topical tacrolimus and pimecrolimus in the treatment of oral lichen planus: An update. J Oral Pathol Med 2010;39:201-5.
27. Omidian M, Ayooobi A, Mapar M, Feity A, Cheraghian B. Efficacy of sulfasalazine in the treatment of generalized lichen planus: Randomized double-blinded clinical trial on 52 patients. J Eur Acad Dermatol Venerol 2010;24:1051-4.
28. Ruby AJ, Kuttan G, Babu KD, Rajasekharan KN, Kuttan R. Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett 1995;94:79-83.
29. Naqal M, Sood S. Role of curcumin in systemic and oral health: An overview. J Nat Sci Biol Med 2013;4:3-7.
30. Wei A, Shibamoto T. Antioxidant/lipoxygenase inhibitory activities and chemical compositions of selected essential oils. J Agric Food Chem 2010;58:7218-25.
31. Davis SC, Perez R. Cosmeceuticals and natural products: Wound healing. Clin Dermatol 2009;27:502-9.
32. Thingprasom K, Carrozzo M, Furness S, Lodi G. Interventions for treating oral lichen planus. Cochrane Database Syst Rev 2011;7:CD001168.
33. Singh SS, Chokshi K, Desai S, Malu R, Chokshi A. medical management of oral lichen planus: A systematic review. J Clin Diagn Res 2016;10:ZE10-5.